查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2030103

細胞和基因治療藥物輸送裝置市場－全球產業規模、佔有率、趨勢、機會及預測：按類型、給藥途徑、方法、地區和競爭格局分類，2021-2031年

Cell & Gene Therapy drug Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type, By Route of Administration, By Method, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球細胞和基因治療藥物輸送設備市場預計將從 2025 年的 15.6 億美元成長到 2031 年的 27.9 億美元，複合年成長率為 10.17%。

該市場涵蓋了用於精準高效地向患者輸送遺傳物質和治療性細胞的專用技術。推動這項市場擴張的關鍵因素包括研發投入的大幅成長、先進療法監管核准的不斷增加，以及大量創新治療方法正在進行臨床試驗。為了佐證這一趨勢，再生醫學聯盟報告稱，到2025年，該領域已透過216輪資金籌措籌集了111億美元。此外，監管活動也在加速推進。歐洲藥品管理局（EMA）先進療法委員會於2025年4月批准了Vyjuvek的上市核准，並於2025年5月對Aucatzyl發布了積極意見。

市場概覽
預測期 2027-2031
市場規模：2025年 15.6億美元
市場規模：2031年 27.9億美元
複合年成長率：2026-2031年 10.17%
成長最快的細分市場 預填充式注射器
最大的市場 北美洲

另一方面，該市場面臨許多挑戰，包括高昂的製造成本以及開發高度專業化的遞送系統和相應治療藥物的複雜性。儘管如此，該領域仍在穩步發展。正如再生醫學聯盟所指出的，2025年兩款重磅細胞和基因治療產品的上市凸顯了這些最先進治療的巨大商業性潛力以及日益成長的患者可及性。

市場促進因素

細胞和基因療法監管核准數量的不斷增加是推動全球該領域藥物遞送設備市場發展的主要動力。隨著更多先進治療方法的核准，對精準高效遞送機制的需求也顯著成長。這些法規核准驗證了這些治療方法的臨床價值，並鼓勵對相關遞送技術進行持續投資。例如，美國食品藥物管理局 (FDA) 於 2025 年 12 月 9 日核准Waskyra®（etuvetidigene autotemcel）用於核准Wiscott-Aldrich 症候群，並於 2025 年 4 月 29 日批准 Zevaskyn（prademagene zamikeracel）用於治療隱性滋養型水痘性先天性水皰症，這凸顯了人們對基因矯正療法的日益成長的支持。這些突破性的核准將直接刺激對旨在安全高效遞送複雜生物有效載荷的專用設備的需求，最終擴大依賴先進遞送系統的患者群體。

此外，細胞和基因遞送平台的技術突破是市場成長的關鍵驅動力。這些創新致力於提升遞送技術的安全性、效率和標靶精準度，這些都是有效實施這些治療方法的必要要素。關鍵進展包括非病毒遞送機制的改進和創新的病毒載體工程。例如，美國國立衛生研究院 (NIH) 於 2026 年 4 月發表的一篇報導“NIH 資助的突破：將 CRISPR 微型化以實現體內精準遞送”的文章，詳細介紹了一種新發現的、使用 Al3Cas12f 酶的緊湊型 CRISPR 基因編輯系統。該系統可無縫整合到腺結合病毒(AAV) 載體中，從而實現精準標靶化。這些突破將使更多疾病的治療成為可能，並透過高度精準的給藥來改善患者的治療效果。全球趨勢也反映了這一發展動能。根據再生醫學聯盟發布的 2025 年第三季行業概覽，亞太地區將在 2025 年的臨床試驗數量上超過北美，凸顯了對先進輸送設備的地理需求不斷擴大。

市場挑戰

細胞和基因治療藥物遞送裝置在全球市場的主要障礙在於其固有的複雜性和高昂的生產成本，這些複雜性和成本與製造專用遞送系統及其治療有效載荷密切相關。通常，這些生產流程依賴過時且資源密集的技術，難以規模化生產，導致治療成本居高不下，並限制了患者獲得這些前沿療法的機會。擴大治療藥物及其複雜遞送系統的先進製造能力所需的大量資本投入構成了重大的經濟障礙，限制了市場滲透率和這些開創性醫療解決方案的整體覆蓋範圍。

這一沉重的經濟負擔正嚴重阻礙市場成長，並推高病患和醫療網路的治療成本。因此，亟需大量資金籌措來緩解這些高昂的成本。例如，再生醫學聯盟發布的2025年第三季產業概覽報告顯示，Kernal Bio已籌集4,800萬美元用於開發更經濟實惠的CAR-T細胞療法，凸顯了為解決這些根本性的財務障礙而調動的巨額資金籌措。最終，這些治療組件的高昂製造成本導致聯合療法和給藥裝置的價格飆升，阻礙了該行業實現廣泛的商業化和患者可及性。

市場趨勢

全球細胞和基因治療藥物輸送設備市場正受到以患者為中心、以家庭為基礎的給藥機制的顯著影響，這種機制優先考慮易用性和擴大治療覆蓋範圍。這一趨勢正在加速開發侵入性更小、更易於操作且可在傳統醫療機構之外使用的藥物傳輸工具。這些改進對於需要持續或重複給藥的療法尤其重要，能夠顯著減輕醫療系統和患者的負擔。為了支持這項向快速個人化治療的轉變，創新基因組學研究所於2025年7月發布的最新報告《CRISPR臨床試驗：2025年最新進展》指出，首個個人化CRISPR療法在短短六個月內便研發成功並應用於患者。

另一個正在改變行業的重大趨勢是供應鏈流程的數位化和自動化，這顯著提高了品管、可擴充性和生產效率。這些進步有助於解決細胞和基因療法研發過程中面臨的高成本和高度複雜的挑戰，因為這些療法依賴高度專業化的組件和複雜的流程。透過將數位化平台和自動化設備整合到生產和供應鏈中，企業可以確保批次間的一致性，減少人為錯誤，並簡化整個流程的操作。作為這項進步的象徵性例證，Lonza於2025年12月11日宣布，其Cocoon®平台已獲得美國FDA頒發的先進製造技術（AMT）認證。該認證認可了該平台封閉式自動化細胞療法生產設計，預計將簡化監管流程並促進該技術的更廣泛應用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：細胞與基因治療藥物給藥裝置的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（視網膜下輸注套管、延長管、靜脈導管、無菌胰島素注射器、預填充式注射器、輸液袋）
    • 給藥途徑（口服、靜脈注射、眼內注射、經皮、其他）
    • 方法（體外、離體）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美細胞與基因治療藥物給藥裝置的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲細胞與基因治療藥物給藥裝置的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區細胞與基因治療藥物給藥裝置的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲細胞與基因治療藥物給藥裝置的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美細胞與基因治療藥物給藥裝置的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：細胞與基因治療藥物給藥裝置的全球市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Becton Dickinson and Company
  • Novartis AG
  • Amgen Inc.
  • Kite Pharma Inc.
  • Pfizer Inc.
  • Bausch & Lomb Incorporated
  • Bluebird bio Inc.
  • Castle Creek Biosciences Inc
  • Dendreon Pharmaceuticals LLC
  • Helixmith Co. Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 7364

The Global Cell & Gene Therapy Drug Delivery Devices Market is anticipated to expand from USD 1.56 billion in 2025 to USD 2.79 billion by 2031, reflecting a compound annual growth rate (CAGR) of 10.17%. This market comprises specialized technologies created to precisely and effectively administer genetic material and therapeutic cells to patients. Primary catalysts for this expansion include heavy investments in research and development, a rising number of regulatory clearances for advanced therapies, and a strong pipeline of innovative treatments moving through clinical phases. Highlighting this trend, the Alliance for Regenerative Medicine reported that the sector raised $11.1 billion across 216 financing rounds in 2025. Furthermore, accelerated regulatory momentum is evident, as the European Medicines Agency's Committee for Advanced Therapies granted marketing authorization for Vyjuvek in April 2025 and issued a positive draft opinion for Aucatzyl in May 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.56 Billion
Market Size 2031USD 2.79 Billion
CAGR 2026-203110.17%
Fastest Growing SegmentPrefilled Syringe
Largest MarketNorth America

Conversely, the market faces a notable obstacle in the form of high manufacturing costs and the complex nature of developing these highly specialized delivery systems and their corresponding therapeutic payloads. Nevertheless, the sector is steadily moving forward despite these barriers. As noted by the Alliance for Regenerative Medicine, the introduction of two new blockbuster cell and gene therapy products in 2025 highlights the strong commercial potential and the growing availability of these cutting-edge treatments for patients.

Market Driver

The rising number of regulatory authorizations for cell and gene therapies is a major catalyst for the global drug delivery devices market in this sector. As additional advanced treatments secure approval, the necessity for accurate and effective delivery mechanisms grows substantially. Such regulatory endorsements confirm the clinical value of these treatments, stimulating ongoing investment in the accompanying delivery technologies. For example, the FDA's authorization of Waskyra(R) (etuvetidigene autotemcel) for Wiskott-Aldrich syndrome on December 9, 2025, and Zevaskyn (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa on April 29, 2025, underscores a rising embrace of gene-corrected solutions. These milestone approvals directly stimulate demand for specialized equipment designed to safely and efficiently deliver intricate biological payloads, ultimately expanding the patient population reliant on sophisticated delivery systems.

Additionally, technological breakthroughs in cell and gene delivery platforms act as a critical force propelling market growth. These innovations are centered on improving the safety, efficiency, and targeting precision of delivery techniques, all of which are essential for the effective implementation of these therapies. Key progress includes enhanced non-viral delivery mechanisms and innovative viral vector engineering. Demonstrating this progress, an April 2026 article by the National Institutes of Health, titled "NIH-funded breakthrough shrinks CRISPR for precision delivery in the body," detailed a newly discovered, compact CRISPR gene-editing system using the Al3Cas12f enzyme, which fits seamlessly within adeno-associated virus vectors for precise targeting. Such leaps forward allow for the management of a broader spectrum of diseases and yield better patient results through highly accurate administration. Moreover, global research trends mirror this momentum; the Alliance for Regenerative Medicine's Q3 2025 Sector Snapshot revealed that the Asia-Pacific region overtook North America in clinical trial volume during 2025, highlighting a geographically expanding requirement for advanced delivery apparatuses.

Market Challenge

A primary hurdle restricting the global cell and gene therapy drug delivery devices market is the underlying complexity and steep production expenses linked to manufacturing specialized delivery systems alongside their therapeutic payloads. Frequently, these production workflows depend on older, resource-heavy technologies that are challenging to scale, driving up the cost of therapy and restricting patient availability to these modern treatments. The massive financial investment needed to expand sophisticated manufacturing operations for both the therapies and their complex delivery vehicles forms a formidable economic obstacle, limiting wider market adoption and the overall reach of these pioneering medical solutions.

This significant economic strain actively slows market growth by escalating treatment expenses for both patients and healthcare networks. Consequently, there is a clear demand for substantial funding to help alleviate these prohibitive costs. As an illustration, the Alliance for Regenerative Medicine's Q3 2025 Sector Snapshot reported that Kernal Bio received $48 million in funding to formulate more affordable CAR-T cell therapies, highlighting the immense capital being mobilized to tackle these fundamental financial barriers. Ultimately, the high production costs of these therapeutic elements result in steeper price tags for the combined therapy and delivery device, hindering the industry's capacity to reach broad commercialization and widespread patient access.

Market Trends

The Global cell and gene therapy drug delivery devices market is being heavily shaped by a shift toward patient-focused and home-based delivery mechanisms, which emphasize ease of use and broader treatment accessibility. This movement is accelerating the creation of delivery tools that are less intrusive, easier to handle, and capable of being used away from conventional medical facilities. These improvements are especially vital for treatments that demand ongoing or repeated dosing, as they significantly lessen the strain on both healthcare systems and the patients themselves. Highlighting this push for swift, customized care, a July 2025 update by the Innovative Genomics Institute on "CRISPR Clinical Trials: A 2025 Update" noted that the first personalized CRISPR therapy was successfully created and administered to a patient within a mere six-month timeframe.

Another prominent trend transforming the industry is the digitalization and automation of delivery processes, which drastically improve quality control, scalability, and production efficiency. Such advancements help counteract the high expenses and profound complexities tied to the creation of cell and gene therapies, which rely on highly specialized parts and complicated procedures. By incorporating digital platforms and automated machinery into the production and delivery chains, companies can ensure batch uniformity, reduce human mistakes, and streamline overall operations. Exemplifying this progress, Lonza announced on December 11, 2025, in "Lonza's Cocoon(R) Platform Receives Advanced Manufacturing Technologies (AMT) Designation From The U.S. FDA," that its Cocoon(R) Platform earned this designation from the U.S. FDA, an acknowledgment of its enclosed, automated cell therapy manufacturing design that is expected to ease regulatory pathways and encourage wider technological utilization.

Key Market Players

  • Becton Dickinson and Company
  • Novartis AG
  • Amgen Inc.
  • Kite Pharma Inc.
  • Pfizer Inc.
  • Bausch & Lomb Incorporated
  • Bluebird bio Inc.
  • Castle Creek Biosciences Inc
  • Dendreon Pharmaceuticals LLC
  • Helixmith Co. Ltd

Report Scope

In this report, the Global Cell & Gene Therapy drug Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell & Gene Therapy drug Delivery Devices Market , By Type

  • Subretinal Injection Cannula
  • Extension Tube
  • Intravenous Catheter
  • Sterile Insulin Syringe
  • Prefilled Syringe
  • Infusion Bags

Cell & Gene Therapy drug Delivery Devices Market , By Route of Administration

  • Oral
  • Intravenous
  • Ocular
  • Transdermal
  • Others

Cell & Gene Therapy drug Delivery Devices Market , By Method

  • In Vitro
  • Ex Vivo

Cell & Gene Therapy drug Delivery Devices Market , By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell & Gene Therapy drug Delivery Devices Market .

Available Customizations:

Global Cell & Gene Therapy drug Delivery Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell & Gene Therapy drug Delivery Devices Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
    • 5.2.2. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others)
    • 5.2.3. By Method (In Vitro, Ex Vivo)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Cell & Gene Therapy drug Delivery Devices Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Method
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Method
    • 6.3.2. Canada Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Method
    • 6.3.3. Mexico Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Method

7. Europe Cell & Gene Therapy drug Delivery Devices Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Method
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Method
    • 7.3.2. France Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Method
    • 7.3.3. United Kingdom Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Method
    • 7.3.4. Italy Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Method
    • 7.3.5. Spain Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Method

8. Asia Pacific Cell & Gene Therapy drug Delivery Devices Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Method
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Method
    • 8.3.2. India Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Method
    • 8.3.3. Japan Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Method
    • 8.3.4. South Korea Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Method
    • 8.3.5. Australia Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Method

9. Middle East & Africa Cell & Gene Therapy drug Delivery Devices Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Method
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Method
    • 9.3.2. UAE Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Method
    • 9.3.3. South Africa Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Method

10. South America Cell & Gene Therapy drug Delivery Devices Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Method
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Method
    • 10.3.2. Colombia Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Method
    • 10.3.3. Argentina Cell & Gene Therapy drug Delivery Devices Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Method

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cell & Gene Therapy drug Delivery Devices Market : SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Becton Dickinson and Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Amgen Inc.
  • 15.4. Kite Pharma Inc.
  • 15.5. Pfizer Inc.
  • 15.6. Bausch & Lomb Incorporated
  • 15.7. Bluebird bio Inc.
  • 15.8. Castle Creek Biosciences Inc
  • 15.9. Dendreon Pharmaceuticals LLC
  • 15.10. Helixmith Co. Ltd

16. Strategic Recommendations

17. About Us & Disclaimer